Kiniksa Pharmaceuticals International, plc
KNSANASDAQHealthcareDrug Manufacturers - Specialty & Generic
As of Oct 16, 2026 close
- Market cap
- $6.67B
- P/E (TTM)
- 82.66
- Forward P/E
- 39.99
- Dividend yield
- -
- 52-week range
- $35.20$82.94
- Volume (live)
- -
- Avg. volume (3M)
- 564.67K
Kiniksa Pharmaceuticals International (KNSA) Stock Price & Financial Analysis
Kiniksa Pharmaceuticals International Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $76.88 - $80.34 |
|---|---|
| 52-Week High | $82.94 |
| 52-Week Low | $35.20 |
| Open | $79.94 |
| Volume (last close) | 524.76K |
| Average Volume (3M) | 564.67K |
| Revenue (TTM) | 840.85M |
|---|---|
| Net Income (TTM) | 80.66M |
| Free Cash Flow (TTM) | 183.10M |
| EPS (TTM) | $1.00 |
| Profit Margin | 9.59% |
| Operating Margin | 11.92% |
| Return on Equity (ROE) | 12.33% |
| Debt to Equity | 0.01 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 6.67B |
|---|---|
| Shares Outstanding | 83.40M |
| P/E Ratio (TTM) | 82.66 |
| Forward P/E | 39.99 |
| Price to Sales (P/S) | 7.93 |
| Price to Book (P/B) | 10.19 |
| EV/EBITDA | 59.81 |
| 50-Day MA | $77.76 |
|---|---|
| 200-Day MA | $57.65 |
| 1-Year Change | +106.88% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Kiniksa Pharmaceuticals International at a Glance
As of the Oct 16, 2026 close, Kiniksa Pharmaceuticals International (KNSA) has a market capitalization of $6.67B. The stock trades at 82.7× trailing earnings, 40.0× forward earnings and 7.9× sales. Over the trailing twelve months it earned $80.66M on revenue of $840.85M (a 9.6% profit margin) and generated $183.10M of free cash flow. Revenue grew 58.9% year over year.
As of its latest reported balance sheet, it holds $175.68M in cash and securities against $8.90M of debt, a net cash position of $166.78M.
Kiniksa Pharmaceuticals International does not currently pay a dividend.
The share price is up 106.9% over the past year. At $78.59 (the Oct 16, 2026 close) it sits near the top of its 52-week range of $35.20 to $82.94, above its 200-day moving average of $57.65.
Based on 8 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $96.57, 22.9% above the Oct 16, 2026 close.
Frequently Asked Questions About Kiniksa Pharmaceuticals International
What is the current stock price for KNSA?
As of the Oct 16, 2026 close, KNSA stock trades at $78.59. The 52-week range is $35.20–$82.94, with a day range of $76.88–$80.34.
What is the P/E ratio for KNSA?
As of the Oct 16, 2026 close, Kiniksa Pharmaceuticals International's trailing twelve-month (TTM) P/E ratio is 82.7, meaning investors pay $82.7 for every $1 of annual earnings. The forward P/E is 40.0, reflecting analyst expectations for future earnings. Kiniksa Pharmaceuticals International operates in the Healthcare sector.
Does KNSA pay dividends?
Kiniksa Pharmaceuticals International does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for KNSA?
Based on ratings from 8 professional analysts over the last 90 days, the consensus for KNSA is Buy. The average 12-month price target is $96.57, a 22.9% upside from the Oct 16, 2026 close of $78.59.
What is the market cap of KNSA?
As of the Oct 16, 2026 close, Kiniksa Pharmaceuticals International's market capitalization is $6.55B, classifying it as a mid-cap company. Kiniksa Pharmaceuticals International operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.